HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.

Kristof Theys, Jurgen Vercauteren, Joke Snoeck, Maurizio Zazzi, Ricardo Jorge Camacho, Carlo Torti, Eugen Schülter, Bonaventura Clotet, A Sonnerborg, A. De Luca, Zehava Grossman, Daniel Struck, Anne-mieke Vandamme, Ana Abecasis

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Subtype-dependent selection of HIV-1 reverse transcriptase resistance mutation K65R was previously observed in cell culture and small clinical investigations. We compared K65R prevalence across subtypes A, B, C, F, G, and CRF02_AG separately in a cohort of 3,076 patients on combination therapy including tenofovir. K65R selection was significantly higher in HIV-1 subtype C. This could not be explained by clinical and demographic factors in multivariate analysis, suggesting subtype sequence-specific K65R pathways.
Original languageEnglish
Pages (from-to)1053-6
JournalAntimicrobial Agents and Chemotherapy
Volume57
Issue number2
DOIs
Publication statusPublished - 1 Jan 2013

UN Sustainable Development Goals (SDGs)

  • SDG 3 - Good Health and Well-Being

Fingerprint Dive into the research topics of 'HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.'. Together they form a unique fingerprint.

Cite this